Literature DB >> 26855511

A Prospective Study of Adequacy of Anticoagulation with Fixed Dose Weight Adjusted Unfractionated Heparin in Patients with Deep Vein Thrombosis.

Subash Chandra Bose1, Rakhee Kar2, Suryanarayana Bettadpura Shamanna1.   

Abstract

Weight adjusted fixed dose subcutaneous unfractionated heparin (UFH) is one of the options for the treatment of deep vein thrombosis (DVT), but the degree of its anticoagulant effect has not been tested in India. This was a prospective observational study, conducted at a tertiary care hospital in South India between September 2012 and March 2014. DVT was diagnosed using compression ultrasonography. UFH was given as an initial loading dose of 333 U/kg followed by a maintenance dose of 250 U/kg twice daily subcutaneously. aPTT was done on day 2 and day 4 after 6 h of the morning dose of heparin. Patients were categorized based on aPTT ratios. Fifty five patients treated for proximal lower limb DVT had received UFH. Their median age was 41 years. DVT was secondary to malignancy, immobilisation or pro-coagulant state. No obvious etiology was found in 47 % of the patients. The mean aPTT on day 2 was 41.8 s and 51.7 s on day 4. The aPTT ratio was subtherapeutic in 63.6 % and therapeutic in 32.7 % of the patients on day 2. Five patients had adverse events in the hospital. Three patients died and two other patients had confirmed pulmonary embolism. Death was due to pulmonary embolism in one patient and metastatic malignancies in the other two. No bleeding manifestation had occurred. Caution is required in implementing this UFH regimen as this preliminary investigation has found predominantly subtherapeutic aPTT ratios during the initial phase of anticoagulation.

Entities:  

Keywords:  Anticoagulation; Deep vein thrombosis; Pulmonary embolism; Unfractionated heparin

Year:  2015        PMID: 26855511      PMCID: PMC4733679          DOI: 10.1007/s12288-015-0563-9

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  10 in total

1.  A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study.

Authors:  F A Anderson; H B Wheeler; R J Goldberg; D W Hosmer; N A Patwardhan; B Jovanovic; A Forcier; J E Dalen
Journal:  Arch Intern Med       Date:  1991-05

2.  Treating acute venous thromboembolism--shift with care.

Authors:  Mary Cushman
Journal:  N Engl J Med       Date:  2013-07-01       Impact factor: 91.245

3.  Optimal dosing of subcutaneous unfractionated heparin for the treatment of deep vein thrombosis.

Authors:  C Kearon; L Harrison; M Crowther; J S Ginsberg
Journal:  Thromb Res       Date:  2000-03-15       Impact factor: 3.944

Review 4.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

5.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

6.  Risk of fatal pulmonary embolism in patients with treated venous thromboembolism.

Authors:  J D Douketis; C Kearon; S Bates; E K Duku; J S Ginsberg
Journal:  JAMA       Date:  1998-02-11       Impact factor: 56.272

7.  Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism.

Authors:  Clive Kearon; Jeffrey S Ginsberg; Jim A Julian; James Douketis; Susan Solymoss; Paul Ockelford; Sharon Jackson; Alexander G Turpie; Betsy MacKinnon; Jack Hirsh; Michael Gent
Journal:  JAMA       Date:  2006-08-23       Impact factor: 56.272

8.  Validation of a dosing regimen for fixed-dose, weight-adjusted, subcutaneous unfractionated heparin for the acute treatment of venous thrombo-embolism in a population from a resource-constrained environment.

Authors:  J I Munsamy; H Kertland; A Parrish
Journal:  S Afr Med J       Date:  2010-07-05

Review 9.  Pulmonary embolism and deep vein thrombosis.

Authors:  Samuel Z Goldhaber; Henri Bounameaux
Journal:  Lancet       Date:  2012-04-10       Impact factor: 79.321

10.  Deep vein thrombosis is not rare in Asia--the Singapore General Hospital experience.

Authors:  L H Lee; K Q Gu; D Heng
Journal:  Ann Acad Med Singapore       Date:  2002-11       Impact factor: 2.473

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.